Cargando…

507. Epidemiology of Community-Associated Carbapenemase + Producing Carbapenem-Resistant Enterobacteriacae Identified from the Emerging Infections Program, 2012–2017

BACKGROUND: Carbapenemase-producing (CP-) carbapenem-resistant Enterobacteriaceae (CRE) have been almost exclusively linked to extensive healthcare exposure and are of significant concern due to limited treatment options and potential for plasmid-mediated spread of resistance. We report on CP-CRE in...

Descripción completa

Detalles Bibliográficos
Autores principales: See, Isaac, Ansari, Uzma, Reses, Hannah, Grass, Julian E, Epson, Erin, Nadle, Joelle, Bamberg, Wendy M, Janelle, Sarah J, Bower, Chris W, Jacob, Jesse T, Vaeth, Elisabeth, Wilson, Lucy E, Lynfield, Ruth, VonBank, Brittany, Snippes Vagnone, Paula, Hancock, Emily B, Phipps, Erin C, Dumyati, Ghinwa, Tsay, Rebecca, Cassidy, Maureen, Kainer, Marion A, Mounsey, Jacquelyn, Muleta, Daniel, Bulens, Sandra N, Karlsson, Maria, Duffy, Nadezhda, Lutgring, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811287/
http://dx.doi.org/10.1093/ofid/ofz360.576
_version_ 1783462445471236096
author See, Isaac
Ansari, Uzma
Reses, Hannah
Grass, Julian E
Epson, Erin
Nadle, Joelle
Bamberg, Wendy M
Janelle, Sarah J
Bower, Chris W
Jacob, Jesse T
Vaeth, Elisabeth
Wilson, Lucy E
Lynfield, Ruth
VonBank, Brittany
Snippes Vagnone, Paula
Hancock, Emily B
Phipps, Erin C
Dumyati, Ghinwa
Tsay, Rebecca
Cassidy, Maureen
Kainer, Marion A
Mounsey, Jacquelyn
Muleta, Daniel
Bulens, Sandra N
Karlsson, Maria
Duffy, Nadezhda
Lutgring, Joseph
author_facet See, Isaac
Ansari, Uzma
Reses, Hannah
Grass, Julian E
Epson, Erin
Nadle, Joelle
Bamberg, Wendy M
Janelle, Sarah J
Bower, Chris W
Jacob, Jesse T
Vaeth, Elisabeth
Wilson, Lucy E
Lynfield, Ruth
VonBank, Brittany
Snippes Vagnone, Paula
Hancock, Emily B
Phipps, Erin C
Dumyati, Ghinwa
Tsay, Rebecca
Cassidy, Maureen
Kainer, Marion A
Mounsey, Jacquelyn
Muleta, Daniel
Bulens, Sandra N
Karlsson, Maria
Duffy, Nadezhda
Lutgring, Joseph
author_sort See, Isaac
collection PubMed
description BACKGROUND: Carbapenemase-producing (CP-) carbapenem-resistant Enterobacteriaceae (CRE) have been almost exclusively linked to extensive healthcare exposure and are of significant concern due to limited treatment options and potential for plasmid-mediated spread of resistance. We report on CP-CRE in community-dwelling individuals. METHODS: We used 2012–2017 active, laboratory and population-based surveillance data for CRE from CDC’s Emerging Infections Program sites (9 sites by 2017). Cases were the first isolation of Escherichia coli, Klebsiella spp., or Enterobacter spp. from a normally sterile body specimen or urine in a surveillance site resident meeting a CRE phenotype (figure) in a 30 day period. Epidemiologic data were obtained from chart review. Cases were community-associated (CA) if not isolated after the first three days of a hospital stay; without inpatient healthcare, dialysis, or surgery in the year prior; and without indwelling medical devices within two days prior to culture. A convenience sample of isolates was tested at CDC by real-time PCR to detect bla(KPC), bla(NDM), bla(OXA-48-like), bla(VIM), or bla(IMP). RESULTS: Of 4023 CRE cases, 699 (17%) were CA, from which 297 isolates were tested; 20 (7%) were CP-CRE, from 18 patients (2 had repeat isolation of the same gene/species). The median age was 68 years (range: 33–91), and 14 (78%) were female. Patients were from 7 sites (range: 1–4/site). Their CP-CRE (10 bla(KPC), 6 bla(NDM), and 2 bla(OXA-48-like)) were from three species (10 K. pneumoniae, 6 E. coli, 2 E. cloacae) and isolated from urine (n = 16) and blood (n = 2). Among those with CP-CRE from urine, 12 (75%) had clinical diagnoses of urinary tract infections and the rest had no infection documented. Overall, 7 (39%) were admitted to a hospital within 30 days of culture; none died during hospitalization. Most (n = 13; 72%) had underlying medical comorbidities, most commonly urinary tract abnormalities (n = 5; 28%) and diabetes mellitus (n = 5; 28%). Three (17%) had international travel within two months prior to culture. CONCLUSION: CA CP-CRE were found in most surveillance sites but are rare, occurring primarily in older patients with underlying medical conditions. Patient interviews are planned to determine whether CA CP-CRE may be associated with distant or undocumented healthcare exposures. [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6811287
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68112872019-10-29 507. Epidemiology of Community-Associated Carbapenemase + Producing Carbapenem-Resistant Enterobacteriacae Identified from the Emerging Infections Program, 2012–2017 See, Isaac Ansari, Uzma Reses, Hannah Grass, Julian E Epson, Erin Nadle, Joelle Bamberg, Wendy M Janelle, Sarah J Bower, Chris W Jacob, Jesse T Vaeth, Elisabeth Wilson, Lucy E Lynfield, Ruth VonBank, Brittany Snippes Vagnone, Paula Hancock, Emily B Phipps, Erin C Dumyati, Ghinwa Tsay, Rebecca Cassidy, Maureen Kainer, Marion A Mounsey, Jacquelyn Muleta, Daniel Bulens, Sandra N Karlsson, Maria Duffy, Nadezhda Lutgring, Joseph Open Forum Infect Dis Abstracts BACKGROUND: Carbapenemase-producing (CP-) carbapenem-resistant Enterobacteriaceae (CRE) have been almost exclusively linked to extensive healthcare exposure and are of significant concern due to limited treatment options and potential for plasmid-mediated spread of resistance. We report on CP-CRE in community-dwelling individuals. METHODS: We used 2012–2017 active, laboratory and population-based surveillance data for CRE from CDC’s Emerging Infections Program sites (9 sites by 2017). Cases were the first isolation of Escherichia coli, Klebsiella spp., or Enterobacter spp. from a normally sterile body specimen or urine in a surveillance site resident meeting a CRE phenotype (figure) in a 30 day period. Epidemiologic data were obtained from chart review. Cases were community-associated (CA) if not isolated after the first three days of a hospital stay; without inpatient healthcare, dialysis, or surgery in the year prior; and without indwelling medical devices within two days prior to culture. A convenience sample of isolates was tested at CDC by real-time PCR to detect bla(KPC), bla(NDM), bla(OXA-48-like), bla(VIM), or bla(IMP). RESULTS: Of 4023 CRE cases, 699 (17%) were CA, from which 297 isolates were tested; 20 (7%) were CP-CRE, from 18 patients (2 had repeat isolation of the same gene/species). The median age was 68 years (range: 33–91), and 14 (78%) were female. Patients were from 7 sites (range: 1–4/site). Their CP-CRE (10 bla(KPC), 6 bla(NDM), and 2 bla(OXA-48-like)) were from three species (10 K. pneumoniae, 6 E. coli, 2 E. cloacae) and isolated from urine (n = 16) and blood (n = 2). Among those with CP-CRE from urine, 12 (75%) had clinical diagnoses of urinary tract infections and the rest had no infection documented. Overall, 7 (39%) were admitted to a hospital within 30 days of culture; none died during hospitalization. Most (n = 13; 72%) had underlying medical comorbidities, most commonly urinary tract abnormalities (n = 5; 28%) and diabetes mellitus (n = 5; 28%). Three (17%) had international travel within two months prior to culture. CONCLUSION: CA CP-CRE were found in most surveillance sites but are rare, occurring primarily in older patients with underlying medical conditions. Patient interviews are planned to determine whether CA CP-CRE may be associated with distant or undocumented healthcare exposures. [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6811287/ http://dx.doi.org/10.1093/ofid/ofz360.576 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
See, Isaac
Ansari, Uzma
Reses, Hannah
Grass, Julian E
Epson, Erin
Nadle, Joelle
Bamberg, Wendy M
Janelle, Sarah J
Bower, Chris W
Jacob, Jesse T
Vaeth, Elisabeth
Wilson, Lucy E
Lynfield, Ruth
VonBank, Brittany
Snippes Vagnone, Paula
Hancock, Emily B
Phipps, Erin C
Dumyati, Ghinwa
Tsay, Rebecca
Cassidy, Maureen
Kainer, Marion A
Mounsey, Jacquelyn
Muleta, Daniel
Bulens, Sandra N
Karlsson, Maria
Duffy, Nadezhda
Lutgring, Joseph
507. Epidemiology of Community-Associated Carbapenemase + Producing Carbapenem-Resistant Enterobacteriacae Identified from the Emerging Infections Program, 2012–2017
title 507. Epidemiology of Community-Associated Carbapenemase + Producing Carbapenem-Resistant Enterobacteriacae Identified from the Emerging Infections Program, 2012–2017
title_full 507. Epidemiology of Community-Associated Carbapenemase + Producing Carbapenem-Resistant Enterobacteriacae Identified from the Emerging Infections Program, 2012–2017
title_fullStr 507. Epidemiology of Community-Associated Carbapenemase + Producing Carbapenem-Resistant Enterobacteriacae Identified from the Emerging Infections Program, 2012–2017
title_full_unstemmed 507. Epidemiology of Community-Associated Carbapenemase + Producing Carbapenem-Resistant Enterobacteriacae Identified from the Emerging Infections Program, 2012–2017
title_short 507. Epidemiology of Community-Associated Carbapenemase + Producing Carbapenem-Resistant Enterobacteriacae Identified from the Emerging Infections Program, 2012–2017
title_sort 507. epidemiology of community-associated carbapenemase + producing carbapenem-resistant enterobacteriacae identified from the emerging infections program, 2012–2017
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811287/
http://dx.doi.org/10.1093/ofid/ofz360.576
work_keys_str_mv AT seeisaac 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017
AT ansariuzma 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017
AT reseshannah 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017
AT grassjuliane 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017
AT epsonerin 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017
AT nadlejoelle 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017
AT bambergwendym 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017
AT janellesarahj 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017
AT bowerchrisw 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017
AT jacobjesset 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017
AT vaethelisabeth 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017
AT wilsonlucye 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017
AT lynfieldruth 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017
AT vonbankbrittany 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017
AT snippesvagnonepaula 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017
AT hancockemilyb 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017
AT phippserinc 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017
AT dumyatighinwa 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017
AT tsayrebecca 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017
AT cassidymaureen 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017
AT kainermariona 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017
AT mounseyjacquelyn 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017
AT muletadaniel 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017
AT bulenssandran 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017
AT karlssonmaria 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017
AT duffynadezhda 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017
AT lutgringjoseph 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017